{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:31:08Z","timestamp":1790487068396,"version":"4.1.0"},"reference-count":144,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T00:00:00Z","timestamp":1515283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"INCT para controle do Cancer","award":["CNPq 573806\/2008-0\/Faperj E26\/170.026\/2008"],"award-info":[{"award-number":["CNPq 573806\/2008-0\/Faperj E26\/170.026\/2008"]}]},{"DOI":"10.13039\/501100004586","name":"Faperj","doi-asserted-by":"publisher","award":["E26\/103.140\/2011 E12\/2011"],"award-info":[{"award-number":["E26\/103.140\/2011 E12\/2011"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Programa de Oncobiologia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Abstract: The introduction of imatinib (IM), a BCR-ABL1 tyrosine kinase inhibitor (TKI), has represented a significant advance in the first-line treatment of chronic myeloid leukemia (CML). However, approximately 30% of patients need to discontinue IM due to resistance or intolerance to this drug. Both resistance and intolerance have also been observed in treatment with the second-generation TKIs\u2014dasatinib, nilotinib, and bosutinib\u2014and the third-generation TKI\u2014ponatinib. The mechanisms of resistance to TKIs may be BCR-ABL1-dependent and\/or BCR-ABL1-independent. Although the role of efflux pump P-glycoprotein (Pgp), codified by the ABCB1 gene, is unquestionable in drug resistance of many neoplasms, a longstanding question exists about whether Pgp has a firm implication in TKI resistance in the clinical scenario. The goal of this review is to offer an overview of ABCB1\/Pgp expression\/activity\/polymorphisms in CML. Understanding how interactions, associations, or cooperation between Pgp and other molecules\u2014such as inhibitor apoptosis proteins, microRNAs, or microvesicles\u2014impact IM resistance risk may be critical in evaluating the response to TKIs in CML patients. In addition, new non-TKI compounds may be necessary in order to overcome the resistance mediated by Pgp in CML.<\/jats:p>","DOI":"10.3390\/molecules23010119","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T12:26:02Z","timestamp":1515414362000},"page":"119","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Towards Comprehension of the ABCB1\/P-Glycoprotein Role in Chronic Myeloid Leukemia"],"prefix":"10.3390","volume":"23","author":[{"given":"Raquel","family":"Maia","sequence":"first","affiliation":[{"name":"Laborat\u00f3rio de Hemato-Oncologia Celular e Molecular and Programa de Hemato-Oncologia Molecular, Instituto Nacional de C\u00e2ncer (INCA), Pra\u00e7a da Cruz Vermelha, 23, 6\u00b0 andar, CEP 20230-130 Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Vasconcelos","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Hemato-Oncologia Celular e Molecular and Programa de Hemato-Oncologia Molecular, Instituto Nacional de C\u00e2ncer (INCA), Pra\u00e7a da Cruz Vermelha, 23, 6\u00b0 andar, CEP 20230-130 Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-1134","authenticated-orcid":false,"given":"Paloma","family":"Souza","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Hemato-Oncologia Celular e Molecular and Programa de Hemato-Oncologia Molecular, Instituto Nacional de C\u00e2ncer (INCA), Pra\u00e7a da Cruz Vermelha, 23, 6\u00b0 andar, CEP 20230-130 Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Rumjanek","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Imunologia Tumoral, Instituto de Bioqu\u00edmica M\u00e9dica Leopoldo de Meis, Universidade Federal do Rio de Janeiro (UFRJ), Av. Carlos Chagas Filho, 373, Cidade Universit\u00e1ria, CEP 21941-902 Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,1,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s13238-010-0016-z","article-title":"Molecular and cellular bases of chronic myeloid leukemia","volume":"1","author":"Chen","year":"2010","journal-title":"Protein Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1001\/jama.285.21.2705-JFD10005-3-1","article-title":"From the Food and Drug Administration","volume":"286","author":"Schwetz","year":"2001","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0b013e31823dec8d","article-title":"Evolution of therapies for chronic myelogenous leukemia","volume":"17","author":"Santos","year":"2011","journal-title":"Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"123","author":"Kantarjian","year":"2014","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov. Today Technol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.blre.2011.02.001","article-title":"Interpretation of cytogenetic and molecular results in patients treated for CML","volume":"25","author":"Vigil","year":"2011","journal-title":"Blood Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"Guilhot","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: Data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: Frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"Shakespeare","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/07357907.2015.1065499","article-title":"BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival","volume":"33","author":"Pagnano","year":"2015","journal-title":"Cancer Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1185\/03007995.2013.858621","article-title":"Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting","volume":"30","author":"Saleh","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_26","first-page":"671702","article-title":"The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia","volume":"2012","author":"Souza","year":"2012","journal-title":"Leuk. Res. Treat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152013804487380","article-title":"New insight into p-glycoprotein as a drug target","volume":"13","author":"Breier","year":"2013","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-pharmtox-010715-103111","article-title":"Toward a Better Understanding of the Complexity of Cancer Drug Resistance","volume":"56","author":"Gottesman","year":"2016","journal-title":"Ann. Rev. Pharmacol. Toxicol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s00018-008-8111-5","article-title":"An overview of cancer multidrug resistance: A still unsolved problem","volume":"65","author":"Lage","year":"2008","journal-title":"Cell. Mol. life Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ccr.2004.08.003","article-title":"Mining our ABCs: Pharmacogenomic approach for evaluating transporter function in cancer drug resistance","volume":"6","author":"Ross","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim. Biophys."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1517\/17425255.2015.1028917","article-title":"Mechanisms and therapeutic potential of inhibiting drug efflux transporters","volume":"11","author":"Klukovits","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428190009060314","article-title":"A role for P-glycoprotein in regulating cell death","volume":"38","author":"Johnstone","year":"2000","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1046\/j.1365-2141.2001.02969.x","article-title":"Cells from chronic myelogenous leukaemia patients at presentation exhibit multidrug resistance not mediated by either MDR1 or MRP1","volume":"114","author":"Carter","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.leukres.2006.07.016","article-title":"Contrasting features of MDR phenotype in leukemias by using two fluorochromes: Implications for clinical practice","volume":"31","author":"Vasconcelos","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cyto.b.20580","article-title":"Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients","volume":"80","author":"Vasconcelos","year":"2011","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.leukres.2013.09.021","article-title":"Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients","volume":"37","author":"Vasconcelos","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Vivona, D., Lima, L.T., Rodrigues, A.C., Bueno, C.T., Alcantara, G.K., Barros, L.S., De Moraes Hungria, V.T., Chiattone, C.S., De Lourdes Lopes Ferrari Chauffaille, M., and Guerra-Shinohara, E.M. (2014). ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncol. Lett.","DOI":"10.3892\/ol.2014.1857"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.leukres.2015.07.006","article-title":"MRP1 and P-glycoprotein expression assays would be useful in the additional detection of treatment non-responders in CML patients without ABL1 mutation","volume":"39","author":"Park","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.leukres.2013.06.014","article-title":"XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells","volume":"37","author":"Silva","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12185-011-0924-6","article-title":"The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia","volume":"94","author":"Razga","year":"2011","journal-title":"Int. J. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4103\/0971-5916.164250","article-title":"Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase","volume":"142","author":"Malhotra","year":"2015","journal-title":"Indian J. Med. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.leukres.2016.10.005","article-title":"Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice","volume":"51","author":"Mencalha","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/leu.2014.6","article-title":"MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure","volume":"28","author":"Agrawal","year":"2014","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2016.179","article-title":"The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment","volume":"31","author":"Eadie","year":"2017","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1134\/S0006297908010045","article-title":"Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib","volume":"73","author":"Stromskaya","year":"2008","journal-title":"Biochem. Biokhimiia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: First-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.leu.2404897","article-title":"Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2","volume":"22","author":"Shukla","year":"2008","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bbapap.2009.02.014","article-title":"A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function","volume":"1794","author":"Fung","year":"2009","journal-title":"Biochim. Biophys."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bcmd.2011.11.001","article-title":"ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib","volume":"48","author":"Vivona","year":"2012","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clpt.2004.09.002","article-title":"Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer","volume":"77","author":"Wong","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/jpet.103.055574","article-title":"Interaction of imatinib mesilate with human P-glycoprotein","volume":"307","author":"Hamada","year":"2003","journal-title":"J. Pharmaco. Exp. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/gm206","article-title":"The pharmacogenetics of imanitib","volume":"2","author":"Dulucq","year":"2010","journal-title":"Genome Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","article-title":"Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia","volume":"28","author":"Ni","year":"2011","journal-title":"Med. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1182\/blood-2010-07-296954","article-title":"Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib","volume":"116","author":"Deenik","year":"2010","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.biopha.2014.01.009","article-title":"Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients","volume":"68","author":"Au","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/jcpt.12424","article-title":"Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia","volume":"41","author":"Adeagbo","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.leukres.2010.12.004","article-title":"Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia","volume":"35","author":"Maffioli","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2012.066480","article-title":"Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy","volume":"98","author":"Angelini","year":"2013","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12032-014-0279-y","article-title":"ABCB1 haplotypes but not individual SNPs predict for optimal response\/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate","volume":"31","author":"Ali","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1179\/1607845413Y.0000000102","article-title":"Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients","volume":"19","author":"Elghannam","year":"2014","journal-title":"Hematology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"Kim","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J. Hum. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.3109\/10428194.2014.893307","article-title":"Polymorphisms in the human organic cation transporter and the multidrug resistance gene: Correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia","volume":"55","author":"Vine","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.1135308","article-title":"A \u201csilent\u201d polymorphism in the MDR1 gene changes substrate specificity","volume":"315","author":"Oh","year":"2007","journal-title":"Science"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/0091270005284387","article-title":"G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression","volume":"46","author":"Song","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s12032-010-9561-9","article-title":"MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: An impact on susceptibility and prognosis","volume":"28","author":"Penna","year":"2011","journal-title":"Med. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1026331326648","article-title":"Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms","volume":"136","author":"Goreva","year":"2003","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1600-0609.2004.00228.x","article-title":"Functional C3435T polymorphism of MDR1 gene: An impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia","volume":"72","author":"Jamroziak","year":"2004","journal-title":"Eur. J. Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"10969","DOI":"10.1007\/s13277-014-2400-4","article-title":"Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia","volume":"35","author":"Yaya","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.clpt.6100201","article-title":"Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype","volume":"82","author":"Gurney","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00280-017-3271-3","article-title":"Association of the hOCT1\/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia","volume":"79","author":"Galeotti","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.tips.2005.06.001","article-title":"A novel way to spread drug resistance in tumor cells: Functional intercellular transfer of P-glycoprotein (ABCB1)","volume":"26","author":"Ambudkar","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/leu.2009.76","article-title":"Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells","volume":"23","author":"Bebawy","year":"2009","journal-title":"Leukemia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.yexcr.2015.06.005","article-title":"Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL","volume":"336","author":"Souza","year":"2015","journal-title":"Exp. Cell Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fonc.2014.00040","article-title":"In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies","volume":"4","author":"McDermott","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1590\/S0001-37652001000100007","article-title":"Multidrug resistance in tumour cells: Characterisation of the multidrug resistant cell line K562-Lucena 1","volume":"73","author":"Rumjanek","year":"2001","journal-title":"An. Acad. Bras. Cienc."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11010-013-1761-0","article-title":"Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms","volume":"383","author":"Vidal","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.leukres.2014.06.001","article-title":"Changes in gene expression profile in two multidrug resistant cell lines derived from a same drug sensitive cell line","volume":"38","author":"Moreira","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.leukres.2014.12.008","article-title":"Drug transporters play a key role in the complex process of Imatinib resistance in vitro","volume":"39","author":"Alves","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcp.2009.04.002","article-title":"Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1\/Pgp and ABCG2\/BCRP\/MXR transporters","volume":"78","author":"Tiwari","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-015-0179-4","article-title":"In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib","volume":"8","author":"Redaelli","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5732\/cjc.011.10327","article-title":"Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells","volume":"31","author":"Peng","year":"2012","journal-title":"Chin. J. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/leu.2009.242","article-title":"Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: Implications for combination TKI therapy","volume":"24","author":"Hiwase","year":"2010","journal-title":"Leukemia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib","volume":"38","author":"Dohse","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood.V93.12.4086","article-title":"Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia","volume":"93","author":"Hu","year":"1999","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0091270007311568","article-title":"P-glycoprotein: So many ways to turn it on","volume":"48","author":"Callaghan","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00432-015-2029-8","article-title":"Membrane microparticles: Shedding new light into cancer cell communication","volume":"142","author":"Faccion","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1096\/fj.11-186817","article-title":"Microparticle-associated nucleic acids mediate trait dominance in cancer","volume":"26","author":"Jaiswal","year":"2012","journal-title":"FASEB J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2013.07.009","article-title":"Microparticles mediate MRP1 intercellular transfer and the re-templating of intrinsic resistance pathways","volume":"76","author":"Lu","year":"2013","journal-title":"Pharmacol. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bbagen.2015.12.011","article-title":"Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells","volume":"1860","author":"Sousa","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1158\/1541-7786.MCR-16-0307","article-title":"Expression Profiling of Circulating Microvesicles Reveals Intercellular Transmission of Oncogenic Pathways","volume":"15","author":"Milani","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.canlet.2014.03.009","article-title":"Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8-dependent survival of leukemia cells","volume":"348","author":"Corrado","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12964-015-0086-x","article-title":"Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism","volume":"13","author":"Raimondo","year":"2015","journal-title":"Cell Commun. Signal."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/jcmm.12873","article-title":"Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor","volume":"20","author":"Corrado","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"9739","DOI":"10.1007\/s13277-015-3741-3","article-title":"High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders","volume":"36","author":"Caivano","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ygyno.2010.06.004","article-title":"MiR-27a modulates MDR1\/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells","volume":"119","author":"Li","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/aps.2013.35","article-title":"Friend or foe: The role of microRNA in chemotherapy resistance","volume":"34","author":"Li","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1126\/science.1149460","article-title":"Switching from repression to activation: MicroRNAs can up-regulate translation","volume":"318","author":"Vasudevan","year":"2007","journal-title":"Science"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12251","article-title":"MicroRNAs and their relevance to ABC transporters","volume":"77","author":"Haenisch","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.28500","article-title":"The network of P-glycoprotein and microRNAs interactions","volume":"135","author":"Seca","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.bcp.2008.06.007","article-title":"Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1\/P-glycoprotein expression in human cancer cells","volume":"76","author":"Zhu","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1089\/dna.2012.1703","article-title":"Regulation exerted by miRNAs in the promoter and UTR sequences: MDR1\/P-gp expression as a particular case","volume":"31","year":"2012","journal-title":"DNA Cell Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/j.1582-4934.2010.01213.x","article-title":"Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia","volume":"15","author":"Feng","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Fei, J., Li, Y., Zhu, X., and Luo, X. (2012). miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML). PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032834"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1755-8166-6-27","article-title":"Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia","volume":"6","author":"Mosakhani","year":"2013","journal-title":"Mol. Cytogenet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/ijlh.12351","article-title":"Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"37","author":"Fallah","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","article-title":"Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia","volume":"95","author":"Flamant","year":"2010","journal-title":"Haematologica"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3892\/or.2017.5464","article-title":"miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1","volume":"37","author":"Li","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Ohyashiki, K., Umezu, T., Katagiri, S., Kobayashi, C., Azuma, K., Tauchi, T., Okabe, S., Fukuoka, Y., and Ohyashiki, J.H. (2016). Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17040570"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.leukres.2017.05.015","article-title":"MicroRNAs that affect the Fanconi Anemia\/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations","volume":"59","author":"Yap","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_119","first-page":"1613","article-title":"Survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells","volume":"25","author":"Silva","year":"2011","journal-title":"Oncol. Rep."},{"key":"ref_120","first-page":"471","article-title":"Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia","volume":"26","author":"Reis","year":"2011","journal-title":"Oncol. Rep."},{"key":"ref_121","first-page":"925","article-title":"P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells","volume":"39","author":"Souza","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.leukres.2012.08.014","article-title":"Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells","volume":"36","author":"Bernardo","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2559.2010.03693.x","article-title":"Cytoplasmic expression of survivin is an independent predictor of poor prognosis in patients with salivary gland cancer","volume":"57","author":"Stenner","year":"2010","journal-title":"Histopathology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1179\/102453311X12940641877803","article-title":"Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib","volume":"16","author":"Seca","year":"2011","journal-title":"Hematology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.V100.5.1910.h81702001910_1910_1912","article-title":"Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase","volume":"100","author":"List","year":"2002","journal-title":"Blood"},{"key":"ref_127","first-page":"419","article-title":"Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: Association of cyclosporin A with etoposide","volume":"16","author":"Maia","year":"1997","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: Implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/sj.leu.2404859","article-title":"ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia","volume":"21","author":"Raaijmakers","year":"2007","journal-title":"Leukemia"},{"key":"ref_132","first-page":"22","article-title":"The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells","volume":"8","author":"Kim","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.3390\/molecules19033356","article-title":"Nilotinib enhances the efficacy of conventional chemotherapeutic drugs in CD34(+)CD38(\u2212) stem cells and ABC transporter overexpressing leukemia cells","volume":"19","author":"Wang","year":"2014","journal-title":"Molecules"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1535-7163.MCT-12-0302","article-title":"The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2","volume":"11","author":"Sen","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1038\/leu.2015.35","article-title":"Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells","volume":"29","author":"Lu","year":"2015","journal-title":"Leukemia"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1042\/BJ20070891","article-title":"Curcumin inhibits FtsZ assembly: An attractive mechanism for its antibacterial activity","volume":"410","author":"Rai","year":"2008","journal-title":"Biochem. J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.canlet.2008.06.031","article-title":"DNA damage and endoplasmic reticulum stress mediated curcumin-induced cell cycle arrest and apoptosis in human lung carcinoma A-549 cells through the activation caspases cascade- and mitochondrial-dependent pathway","volume":"272","author":"Lin","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.bmc.2016.11.023","article-title":"A novel curcumin derivative which inhibits P-glycoprotein, arrests cell cycle and induces apoptosis in multidrug resistance cells","volume":"25","author":"Oliveira","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cbi.2015.12.001","article-title":"Chemosensitizing effects of synthetic curcumin analogs on human multi-drug resistance leukemic cells","volume":"244","author":"Mapoung","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"12793","DOI":"10.3390\/molecules181012793","article-title":"Apoptosis sensitization by Euphorbia factor L1 in ABCB1-mediated multidrug resistant K562\/ADR cells","volume":"18","author":"Zhang","year":"2013","journal-title":"Molecules"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.bmc.2009.12.073","article-title":"New pterocarpanquinones: Synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-alpha modulation in human PBMC cells","volume":"18","author":"Netto","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10637-010-9453-z","article-title":"LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: A novel class of agent with high apoptotic effect in chronic myeloid leukemia cells","volume":"29","author":"Maia","year":"2011","journal-title":"Investig. New Drugs"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/CAD.0b013e3283592da8","article-title":"The pterocarpanquinone LQB 118 induces apoptosis in tumor cells through the intrinsic pathway and the endoplasmic reticulum stress pathway","volume":"24","author":"Costa","year":"2013","journal-title":"Anticancer Drugs"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2174\/18715206113139990108","article-title":"NFkappaB pathway and microRNA-9 and -21 are involved in sensitivity to the pterocarpanquinone LQB-118 in different CML cell lines","volume":"15","author":"Leal","year":"2015","journal-title":"Anticancer Agents Med. Chem."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/1\/119\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:50:23Z","timestamp":1760194223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/1\/119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,7]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"alternative-id":["molecules23010119"],"URL":"https:\/\/doi.org\/10.3390\/molecules23010119","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,7]]}}}